Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now displays a new revision label: Revision: v3.5.3, replacing v3.5.2. This signals an update to the page version, with no evident public content changes.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check53 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page. The change does not modify study data or user-facing functionality.SummaryDifference0.0%

- Check61 days agoChange DetectedSite version updated from v3.4.2 to v3.4.3. No observable changes to the study content or user-visible features.SummaryDifference0.0%

- Check89 days agoChange DetectedA new site revision tag (Revision: v3.4.2) is added, and an older Revision: v3.4.1 tag along with a government funding lapse notice has been removed. These changes are cosmetic and do not affect trial details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check96 days agoChange DetectedA new site-wide notice states that information may not be up to date due to a lapse in government funding and directs users to update status at opm.gov. The page revision has been updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.